Al-Khalidi Banaz, Kimball Samantha M, Rotondi Michael A, Ardern Chris I
School of Kinesiology and Health Science, York University, Toronto, M3J1P3, ON, Canada.
Pure North S'Energy Foundation, Calgary, AB, Canada.
Nutr J. 2017 Feb 28;16(1):16. doi: 10.1186/s12937-017-0237-6.
Previously reported associations between vitamin D status, as measured by serum 25-hydroxyvitamin D [25(OH)D] concentrations, and cardiometabolic risk factors were largely limited by variability in 25(OH)D assay performance. In accordance with the Vitamin D Standardization Program, serum 25(OH)D measurement was recently standardized in the National Health and Nutrition Examination Survey (NHANES) to reduce laboratory and method related differences in serum 25(OH)D results. We evaluated the overall and ethnic-specific associations between the newly standardized serum 25(OH)D concentrations and cardiometabolic risk in U.S. adults.
This study examined standardized 25(OH)D data from five cycles of the NHANES (2001-2010). The total sample included 7674 participants (1794 Mexican-Americans, 4289 non-Hispanic whites, and 1591 non-Hispanic blacks) aged ≥ 20 years who were examined in the morning after overnight fasting. Serum 25(OH)D was directly measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 2007-2010, and was predicted from LC-MS/MS equivalents for 2001-2006. Serum 25(OH)D levels were categorized into quartiles (<43.4, 43.4-58.6, 58.7-74.2, ≥74.3 nmol/L). Cardiometabolic risk was defined by the homeostatic model assessment of insulin resistance (HOMA-IR), metabolic syndrome (MetS), and Framingham cardiovascular disease (CVD) risk. Prevalence ratios and 95% confidence intervals were calculated using modified Poisson regression.
After full adjustment for confounders, serum 25(OH)D ≥74.3 nmol/L was associated with lower cardiometabolic risk compared to 25(OH)D <43.4 nmol/L in the overall sample [HOMA-IR: 0.70 (0.59, 0.84); MetS: 0.82 (0.74, 0.91); CVD risk: 0.78 (0.66, 0.91)]. These associations remained significant in Mexican-Americans [HOMA-IR: 0.54 (0.35, 0.82); MetS: 0.73 (0.55, 0.96)], non-Hispanic whites [HOMA-IR: 0.81 (0.68, 0.96); MetS: 0.84 (0.73, 0.95); CVD risk: 0.78 (0.64, 0.93)]; and in non-Hispanic blacks [HOMA-IR: 0.67 (0.45, 0.99); MetS: 0.75 (0.56, 0.97); CVD risk: 0.58 (0.41, 0.81)].
Low vitamin D status is a significant risk factor for cardiometabolic disease in U.S. adults based on standardized serum 25(OH)D results, irrespective of ethnic background. Future studies using standardized 25(OH)D data are needed to confirm these results, particularly amongst U.S. blacks with 25(OH)D concentrations above 75 nmol/L.
先前报道的通过血清25-羟基维生素D[25(OH)D]浓度衡量的维生素D状态与心血管代谢危险因素之间的关联,很大程度上受到25(OH)D检测性能变异性的限制。根据维生素D标准化计划,血清25(OH)D检测最近在美国国家健康与营养检查调查(NHANES)中实现了标准化,以减少血清25(OH)D检测结果中与实验室和方法相关的差异。我们评估了新标准化的血清25(OH)D浓度与美国成年人心血管代谢风险之间的总体关联以及特定种族关联。
本研究检查了NHANES五个周期(2001 - 2010年)的标准化25(OH)D数据。总样本包括7674名年龄≥20岁的参与者(1794名墨西哥裔美国人、4289名非西班牙裔白人、1591名非西班牙裔黑人),这些参与者在过夜禁食后的早晨接受检查。2007 - 2010年通过液相色谱 - 串联质谱法(LC - MS/MS)直接测量血清25(OH)D,并根据2001 - 2006年LC - MS/MS等效值进行预测。血清25(OH)D水平分为四分位数(<43.4、43.4 - 58.6、58.7 - 74.2、≥74.3 nmol/L)。心血管代谢风险通过胰岛素抵抗稳态模型评估(HOMA - IR)、代谢综合征(MetS)和弗雷明汉心血管疾病(CVD)风险来定义。使用修正的泊松回归计算患病率比和95%置信区间。
在对混杂因素进行全面调整后,与血清25(OH)D<43.4 nmol/L相比,总体样本中血清25(OH)D≥74.3 nmol/L与较低的心血管代谢风险相关[HOMA - IR:0.70(0.59,0.84);MetS:0.82(0.74,0.91);CVD风险:0.78(0.66,0.91)]。这些关联在墨西哥裔美国人[HOMA - IR:0.54(0.35,0.82);MetS:0.73(0.55,0.96)]、非西班牙裔白人[HOMA - IR:0.81(0.68,0.96);MetS:0.84(0.73,0.95);CVD风险:0.78(0.64,0.93)]以及非西班牙裔黑人[HOMA - IR:0.67(0.45,0.99);MetS:0.75(0.56,0.97);CVD风险:0.58(0.41,0.81)]中仍然显著。
基于标准化的血清25(OH)D结果,低维生素D状态是美国成年人心血管代谢疾病的一个重要危险因素,与种族背景无关。需要使用标准化的25(OH)D数据进行进一步研究以证实这些结果,特别是在血清25(OH)D浓度高于纳摩尔/升的美国黑人中。 (注:原文最后一句“特别是在血清25(OH)D浓度高于纳摩尔/升的美国黑人中”这里“高于纳摩尔/升”前面缺少具体数值,译文保留原文缺陷。)